Keith T. Flaherty

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La ...

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF...

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic...

Pathways and therapeutic targets in melanoma

This review aims to summarize the current knowledge of molecular pathways and their clinical relevance in melanoma. Metastatic melanoma was a grim diagnosis, but in recent years...

Final Version of 2009 AJCC Melanoma Staging and Classification

Purpose To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database. Methods Th...

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of pati...

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that the...

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50–70% of malignant melanomas. Pre-clinical studies have demonstrated that the B-RAF(V...